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Deficiency of ACE2 in macrophages has been suggested to promote the development of an inflammatory M1 macrophage
phenotype. We evaluated effects of ACE2 deficiency in bone-marrow-derived stem cells on adipose inflammation and glucose
tolerance in C57BL/6 mice fed a high fat (HF) diet. ACE2 activity was increased in the stromal vascular fraction (SVF) isolated
from visceral, but not subcutaneous adipose tissue of HF-fedmice. Deficiency of ACE2 in bonemarrow cells significantly increased
mRNA abundance of F4/80 and TNF-α in the SVF isolated from visceral adipose tissue of HF-fed chimeric mice, supporting
increased presence of inflammatory macrophages in adipose tissue. Moreover, deficiency of ACE2 in bone marrow cells modestly
augmented glucose intolerance in HF-fed chimeric mice and increased blood levels of glycosylated hemoglobin. In summary, ACE2
deficiency in bone marrow cells promotes inflammation in adipose tissue and augments obesity-induced glucose intolerance.
1. Introduction
Angiotensin-converting enzyme-2 (ACE2) is a mono-
carboxypeptidase which is responsible for converting
angiotensin II (AngII) to angiotensin 1–7 (Ang-(1–7)). Pre-
vious studies demonstrated expression of a complete renin-
angiotensin system (RAS) in bone marrow cells, including
renin, angiotensin converting enzyme (ACE), ACE2, AngII,
and angiotensin receptors (AT1 and AT2) [1, 2]. Recent stud-
ies in our laboratory demonstrated ACE2 enzymatic activity
in macrophages and localization of ACE2 immunoreactivity
to macrophage-containing atherosclerotic lesions [2]. More-
over, deficiency of ACE2 in bone-marrow-derived stem cells
promoted the development of diet-induced atherosclerosis
in low-density-lipoprotein-receptor (LDLR-)deficient mice
[2]. Peritoneal macrophages from ACE2-deficient LDLR−/−
mice exhibited increased release of AngII, IL-6, and plas-
minogen activator inhibitor-1 (PAI-1), and conditioned
media from ACE2-deficient macrophages promoted mono-
cyte adhesion to endothelial cells [2]. These results suggest
that elevated levels of AngII in ACE2-deficient leukocytes
may promote adhesion of monocytes to vascular endothelial
cells. Using bone-marrow-derived macrophages from mice
with combined deficiency of apolipoprotein E and ACE2,
Thomas et al. demonstrated enhanced lipopolysaccharide-
(LPS-) induced mRNA abundance of tumor necrosis factor-
alpha (TNFα), monocyte chemoattractant protein-1 (MCP-
1), interleukin-6 (IL-6), and matrix metalloproteinase-9
(MMP-9) [3]. In addition, the mas receptor was localized
to peritoneal macrophages and Ang-(1–7) decreased LPS-
induced inflammatory responses [4]. Collectively, these
results suggest that macrophage ACE2 influences levels of
AngII/Ang-(1–7), potentially contributing to macrophage-
mediated inflammation.
Obesity is known to increase macrophage infiltration
into adipose tissue, and adipose tissue macrophages (ATMs)
are mainly derived from the bone marrow [5, 6]. Infiltration
of macrophages with obesity promotes inflammation in
adipose tissue and has been linked to the development
of insulin resistance and type 2 diabetes [7]. Adipocytes
secrete a number of different cytokines that can influence
the polarization state of macrophages in adipose tissue.
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Macrophages that are recruited to adipose tissue display an
activated state, termedM1 polarization [8–10]. ActivatedM1
macrophages have increased expression of IL-6, inducible
nitric oxide (iNOS), and C-C chemokine receptor 2 (CCR2)
[8]. Alternatively activated macrophages (M2 polarization)
counterbalance the proinflammatory status in adipose tissue
[9]. Since peritoneal macrophages from ACE2-deficient mice
displayed increased expression and/or release of several M1
macrophage-related cytokines, macrophages from ACE2-
deficient mice have been suggested to exhibit M1 polariza-
tion [2].
Previous studies demonstrated that diet-induced obesity
is associated with an activated systemic and adipose renin-
angiotensin system (RAS) [11, 12]. Increased plasma concen-
trations of AngII in male C57BL/6 mice with diet-induced
obesity were associated with dysregulated ACE2 in adipose
tissue and the development of obesity hypertension [12].
These results suggest that obesity is associated with changes
in the adipose RAS, including ACE2. Since obesity is associ-
ated with increased macrophage infiltration into adipose tis-
sue, the specific cell type(s) experiencing previously observed
alterations in ACE2 function in adipose tissue of obese mice
is unclear [12]. Moreover, the role of macrophage-derived
ACE2 in obesity-induced inflammation of adipose tissue has
not been defined. Bone marrow transplantation in irradiated
mice has been extensively employed to define the role of
leukocytes in various disease pathologies. The purpose of this
study was to define the effect of leukocyte deficiency of ACE2,
using bone marrow transplantation from ACE2-deficient
mice, on the development of obesity, adipose inflammation,
and glucose intolerance in high-fat-(HF-) fed C57BL/6 mice.
2. Methods
2.1. Mice and Bone Marrow Transplantation. All experiments
involving mice conformed to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
and were approved by the University of Kentucky Insti-
tutional Animal Care and Use Committee. Male, 8-week-
old C57BL/6 mice were purchased from Jackson Labs (Bar
Harbor, MA) and housed in a temperature-controlled room
with a 12 : 12-h light-dark cycle. Ace2+/y or Ace2−/y C57BL/6
mice were 10-times backcrossed onto a C57BL/6 background
[13]. Initial studies examined ACE2 activity in the stromal
vascular fraction (SVF) isolated from adipose tissues of
male C57BL/6 mice (2 months of age; N = 10 /group)
fed a low fat (LF; 10% kcal as fat, D12450, Research Diets
Inc, New Brunswick, NJ) or high fat (HF, 60% kcal as
fat, D12492, Research Diets Inc, New Brunswick, NJ) diet
for 16 weeks. For bone marrow transplantation, C57BL/6
male mice (2 months of age) were pretreated with antibiotic
water (sulfatrim, 4 μg/mL) for 1 week prior to irradiation
[2, 14]. Bone marrow was extracted from the tibias and
femurs of Ace2+/y or Ace2−/y male mice (2 months of age)
and injected into gamma-irradiated recipient C57BL/6 males
(N = 15 mice/donor genotype) at a dose of 107 cells per
mouse. Recipient mice were given antibiotic water for 8
weeks to allow for efficient repopulation [14]. Mice in each
Table 1: Characteristics of chimeric HF-fed mice transplanted with
Ace2+/y or −/y bone marrow.
Ace2+/y Ace2−/y
Body weight (g) 45± 1 46± 1
Body fat by DEXA (%) 40± 1 39± 1
Serum cholesterol (mg/dL) 227± 9 240± 12
Serum triglycerides (mg/dL) 91± 9 77± 8
Serum NEFAs (mEq/L) 4.3± 0.3 4.2± 0.4
Plasma renin (ng/mL) 8± 1 5± 1
Plasma AngII (pg/mL) 243± 50 154± 35
Serum ACE activity (nmol/mL/min) 742± 77 686± 96
Data are mean ± SEM from N = 3–11 mice/donor genotype.
donor genotype were fed the HF diet for 4 months. Body
weight was recorded weekly. To define fat/lean mass, Dual
Energy X-ray Absorptiometry (DEXA) was performed on
anesthetized mice prior to initiation of the HF diet and at
study endpoint. At study endpoint, mice were anesthetized
(ketamine/xylazine 100/10mg/kg, ip) for exsanguination to
obtain blood for white cell counts (WBCs, K indicates
1000 per microliter), hemoglobin concentration (grams
per deciliter), and bone marrow (femur) was harvested
to confirm effective bone marrow repopulation (data not
shown).
2.2. Measurement of Plasma and Serum Parameters. Fasting
(6 hr) blood glucose concentrations (mg/dL) were measured
with a glucometer (FreeStyle Strips, Abbott Labs, Alameda,
CA) at 1, 2, and 3 months of HF-feeding. During month
4 of HF feeding, a glucose tolerance test (GTT) was per-
formed on fasted (6 hr) mice. Blood glucose concentrations
were quantified at 0, 15, 30, 60, 90, 125, 160, and 220
minutes after glucose administration (2mg/g glucose, ip).
Percent glycosylated hemoglobin (%GHb) was quantified in
whole blood according to the manufacturer’s instructions
(Glycohemoglobin Reagent Set-Unitized, cat no. G7540-100,
Pointe Scientific, Inc., Canton MI). Plasma concentrations
of insulin were quantified in nonfasted mice by ELISA
according to the manufacturer’s instructions (Millipore
Inc., Billerica, MA). Serum concentrations of cholesterol,
triglyceride, and free fatty acids were quantified using col-
orimetric kits from Wako Pure Chemical Industries (Osaka,
Japan). Serum ACE activity (Table 1) was quantified using
5mM N-Hippuryl-His-Leu as a substrate in 0.4M sodium
borate, pH 8.3 (30min incubation at 37◦C), with 2% o-
phthaldialdehyde added to measure the fluorescence of the
reaction for 10 minutes at room temperature. Reactions were
preincubated with and without captopril (1 μM) for 30 min-
utes at 37◦C to assess specificity. Absorbance wasmeasured at
an excitation of 365 nm and an emission of 495 nm. Specific
activity was normalized to total volume of serum added to
the reaction (2 μLs). Plasma renin concentrations were quan-
tified by incubating mouse plasma (8 μLs) with an excess
of partially purified rat angiotensinogen (from nephrec-
tomized rats) in the presence of ACE inhibition (EDTA,
captopril, 1 μM), followed by quantification of angiotensin
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I concentrations by radioimmunoassay (DiaSorin CA-1553,
Stillwater, MN) [15]. To quantify plasma concentrations of
AngII, plasma was first processed over mini-C18 columns
to concentrate peptides, followed by quantification of AngII
by radioimmunoassay using an anti-rabbit AngII antibody
(1 : 40,000 dilution; Bachem, Torrance, CA) that exhibits
cross reactivity to AngIII (100%), AngIV (75%), butminimal
reactivity to other angiotensins [14, 16].
2.3. Isolation of Stromal Vascular Fraction (SVF) from Adi-
pose Tissue and Quantification of ACE2 Enzymatic Activity.
Adipose tissue (epididymal fat, EF; retroperitoneal fat, RPF;
subcutaneous fat, SubQ) was minced and digested with
Type I collagenase (1mg/mL; 60min at 37◦C) in buffer
containing fatty acid-free bovine serum albumin (1%) [17].
Digested material was filtered (100 μm nylon mesh) and
centrifuged (500 g) for 10 minutes to pellet SVF (frozen
at −70◦C unless used for ACE2 activity). ACE2 enzymatic
activity was quantified in SVF by examining the conver-
sion of [125I]-AngII to [125I]-Ang-(1–7) [2, 12]. Briefly,
SVF was homogenized in Tris buffer (100mM) containing
NaCl (0.3M), ZnCl2 (10 μM), and Z-proprolinal (10 μM).
Following centrifugation (30,000 g for 20 minutes, 4◦C),
pellets were reconstituted in the above buffer containing
0.5% Triton-X and incubated overnight at 4◦C. Samples
were again centrifuged (5,000 g for 10 minutes, 4◦C) and
the supernatant containing solubilized membrane was used
for measurement of protein (BCA assay, ThermoFischer)
and ACE2 enzymatic activity. SVF protein (0.05mg/mL) was
added to tubes with Tris buffer (total volume was 250 μLs)
containing the following inhibitors: thiorphan (0.1mM),
phosphoramidon (0.1mM), bestatin (100 μM), pepstatin
A (100 μM), and captopril (10 μM) (pH = 7.0). [125I]-
AngII (2 × 106 cpms) was incubated with samples for 30
minutes at 37◦C and the reactions were stopped by adding
50 μLs of 1% phosphoric acid. Samples were centrifuged,
filtered, and injected onto a Beckman reverse-phase HPLC
to resolve angiotensins [12]. Retention times for [125I]-
Ang-(1–7) (6.6 minutes) and [125I]-AngII (13.6 minutes)
were used to define HPLC fractions containing angiotensins,
and radioactivity was quantified by gamma counting. ACE2
activity is expressed as femtomoles per milligram protein per
minute, based on the specific activity of [125I]-AngII [12].
2.4. Quantification of mRNA Abundance by RT-PCR. SVF
pellets were placed in RNA lysis buffer (Promega, Madison,
WI), and RNA was extracted using an SV Total RNA
isolation kit (Promega, Madison, WI). RNA absorbance was
measured at 260/280 nm and reverse transcription reactions
were conducted on 0.5 μg of total RNA. Reverse transcription
reactions were performed using a RETROscript kit (Ambion
Inc, Austin, TX) through use of random decamers and heat
denaturation of the RNA. Subsequent PCR analysis was
performed using SYBR Green PCR core reagents (Applied
Biosystems, Foster City, CA), and real-time conditions were
as follows: 2.5 minutes at 95◦C, 40 cycles of 1 minute at
94◦C, 1 minute at reannealing temperature, 1 minute at
72◦C, and a final elongation step at 72◦C for 10 minutes.
Table 2: Primers used in this study.
Gene Primers
F4/80
Forward 5′-CTTTGGCTATGGGCTTCCAGTC-3′
Reverse 5′-GCAAGGAGGACAGAGTTTATCGTG-3′
TNF-α
Forward 5′-CCCACTCTGACCCCTTTACTC-3′
Reverse 5′-TCACTGTCCCAGCATCTTGT-3′
TNF-α
receptor
Forward 5′-CAGTCTGCAGGGAGTGTGAA-3′
Reverse 5′-CACGCACTGGAAGTGTGTCT-3′
CCR2
Forward 5′-AGAGAGCTGCAGCAAAAAGG-3′
Reverse 5′-GGAAAGAGGCAGTTGCAAAG-3′
CCL2
Forward 5′-CCTGCTGCTACTCATTCACC-3′
Reverse 5′-TGTCTGGACCCATTCCTTCT-3′
IL-1beta
Forward 5′-ATCTGGGATCCTCTCCAGCCAAGC-3′
Reverse 5′-AAAGGTTTGGAAGCAGCCCTTCAT-3′
PAI-1
Forward 5′-ACTGCAAAAGGTCAGGATCG-3′
Reverse 5′-ACAAAGGCTGTGGAGGAAGA-3′
Mgl-1
Forward 5′-ATGATGTCTGCCAGAGAACC-3′
Reverse 5′-ATCACAGATTTCAGCAACCTTA-3′
IL-4
Forward 5′-AGAAGGGACGCCATGCACGG-3′
Reverse 5′-ATGCGAAGCACCTTGGAAGCCC-3′
YM-1
Forward 5′-GACCTGCCCCGTTCAGTGCC-3′
Reverse 5′-TGCCAGTCCAGGTTGAGGCCA-3′
Mrc-1
Forward 5′-AGGGCAAGCTGCAAGCAGCA-3′
Reverse 5′-CCCACTGCCAACCACTGCGT-3′
Cyclophilin A was used to control for loading material and
mRNA abundance was quantified using the 2−ΔΔCt method.
Primers for specific genes are listed in Table 2.
2.5. Statistical Analysis. Data are expressed as mean ± SEM.
All data were analyzed using Sigma Stat. For one factor
analysis (diet or genotype), a t-test was used to analyze end-
point measures. For GTTs, a repeated measures two-way
ANOVA was performed with a Holm-Sidak test for multiple
comparisons. Significance was accepted at P > 0.05.
3. Results
3.1. ACE2 Activity is Increased in SVF from Adipose Tissue
of HF-fed Mice. We quantified the effect of HF feeding
on ACE2 activity in peritoneal macrophages (MPM), bone
marrow (BM), and the SVF isolated from different adipose
depots of LF and HF-fed mice. In MPMs and BM, ACE2
activity was not influenced by HF feeding. In contrast, the
SVF isolated from visceral (RPF) adipose tissue, but not
gonadal (EF) or subcutaneous (SubQ) adipose tissue of
HF-fed mice, exhibited significantly increased ACE2 activity
compared to LF-fed controls (Figure 1; P < 0.05 for RPF;
P = 0.06 for EF; P > 0.05 for SubQ).
3.2. Bone Marrow Deficiency of ACE2 Promotes Increases
in Macrophage and Inflammatory Markers and Glucose
Intolerance in HF-fed Mice. Deficiency of ACE2 in bone-
marrow-derived cells had no significant effect on body
weight or fat mass in HF-fed mice (Table 1). In addition,
ACE2 deficiency in bone marrow cells had no significant
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Figure 1: ACE2 activity is increased in the stromal vascular fraction
(SVF) isolated from visceral adipose tissue of HF-fed C57BL/6mice.
ACE2 activity was quantified in mouse peritoneal macrophages
(MPMs), bone marrow (BM), and SVF isolated from epididymal
(EF), retroperitoneal (RPF) or subcutaneous (SubQ) adipose tissue
from LF or HF-fed mice. Data are mean ± SEM from N = 3-4
mice/diet group. ∗: P < 0.05 compared to LF.
effect on several plasma parameters measured inHF-fedmice
(Table 1). Plasma renin (P = 0.06) or AngII concentrations
(P = 0.148) were not statistically different between groups
indicating that the systemic RAS was not influenced by the
bone marrow repopulation. Bone marrow transplantation
had no effect on WBC cell counts (WBC: Ace2+/y , 3.9 ± 1;
Ace2−/y , 3.7 ± 0.2K/μL). However, irradiated mice receiving
donor marrow from each genotype exhibited a significant
reduction in blood hemoglobin (normal range 11–15 g/dL),
but there were no differences between genotypes (Ace2+/y ,
7.6± 0.6; Ace2−/y , 8.7± 0.6 g/dL, P = 0.22).
To define effects of ACE2 deficiency in leukocytes on
expression of M1 polarization markers in adipose tissue,
we quantified mRNA abundance in the SVF isolated from
EF (Figure 2(a)), RPF (Figure 2(b)), and SubQ (Figure 2(c))
of HF-fed mice transplanted with Ace2+/y or −/y bone
marrow. Expression of the macrophage marker, F4/80, was
significantly increased in the SVF isolated from EF and
RPF from HF-fed mice transplanted with bone marrow
from Ace2−/y compared to +/y mice (Figures 2(a) and 2(b);
P < 0.05). In contrast, deficiency of ACE2 in leukocytes
had no significant effect on F4/80 mRNA abundance in the
SVF isolated from SubQ tissue of HF-fed chimeric mice
(Figure 2(c)). In the SVF isolated from RPF of chimeric
Ace2−/y mice, mRNA abundance of TNF-α was significantly
increased compared to controls. However, other M1 markers
(CCR2, EF, P = 0.282, TNFα receptor, Figures 2(a)–2(c);
IL-6, IL-1β, CCL2, PAI-1, Mgl-1(data not shown)) did
not exhibit significant differences in the SVF isolated from
chimeric Ace2−/y compared to +/y mice. We also quantified
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Figure 2: Bone marrow deficiency of ACE2 increases F4/80 and
TNF-α mRNA abundance in the stromal vascular fraction (SVF)
isolated from visceral adipose tissue of HF-fed C57BL/6 mice.
Quantification of mRNA abundance in the SVF isolated from
epididymal adipose (EF, a), retroperitoneal adipose (RPF, b), or
subcutaneous fat (SubQ, c) of chimeric mice transplanted with
Ace2+/y (depicted on the x-axis as +) or −/y (depicted on the x-
axis as−) bone marrow. Data are mean ± SEM from N =3–11
mice/donor genotype. ∗: P < 0.05 compared to +.
M2 markers (IL-4, Ym-1, and Mrc-1) with no significant
differences between genotypes (data not shown).
Chimeric mice transplanted with Ace2−/y bone marrow
exhibited significantly increased blood glucose concentra-
tions at 15, 160, and 220 minutes after a glucose challenge
compared to mice transplanted with Ace2+/y bone marrow
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Figure 3: Bone marrow deficiency of ACE2 augments glucose intolerance at specific time points following glucose injection in HF-fed
C57BL/6 mice. (a) Glucose tolerance tests (GTT) in HF-fed chimeric mice transplanted with bone marrow from Ace2+/y or −/y mice. (b)
Percent glycosylated hemoglobin levels and plasma insulin concentrations (c) in Ace2+/y and −/y chimeric mice. Data are mean ± SEM from
N =8–15 mice/donor genotype. ∗: P < 0.05 compared to Ace2+/y .
(Figure 3(a); P < 0.05). In addition, blood levels of gly-
cosylated hemoglobin were modestly, but not significantly,
increased in plasma from Ace2−/y chimeric mice (Ace2+/y ,
2.9 ± 0.1; Ace2−/y , 3.6 ± 0.4%, Figure 3(b); P = 0.08).
In contrast, plasma concentrations of insulin were not
significantly different between groups (Ace2+/y , 8±2; Ace2−/y ,
9± 1 ng/mL, P = 0.66).
4. Discussion
Results from this study demonstrate that deficiency of ACE2
in leukocytes promotes inflammation in adipose tissue and
results in a modest impairment of glucose tolerance in obese
mice. Initial studies identified an increase in ACE2 activity
in heterogeneous stromal cells isolated from visceral adipose
tissue, but not in more purified populations of peritoneal
or bone marrow macrophages from HF compared to LF-
fed mice. Notably, deficiency of ACE2 in bone-marrow-
derived cells increased F4/80 expression in the SVF of RPF
tissue, suggesting increased infiltration of macrophages into
adipose tissue of chimeric mice lacking ACE2 in leukocytes.
Moreover, expression of TNF-α was increased in the SVF
of RPF tissue from chimeric mice lacking ACE2 in bone
marrow, supporting increased adipose inflammation from
deficiency of ACE2. Finally, obesity-induced impairment of
glucose homeostasis was modestly augmented in chimeric
ACE2-deficient mice. These results suggest that deficiency of
ACE2 in leukocytes promotes adipose tissue inflammation
and augments the development of obesity-induced diabetes.
Initial studies examined effects of diet-induced obesity
on ACE2 activity in macrophages isolated from the peri-
toneal cavity, bone marrow, or the stromal vascular fraction
of adipose tissue from different regions. Of these different
cell isolations, the SVF included several other cell types
in addition to macrophages. Notably, ACE2 activity was
increased by HF-feeding in the SVF isolated from visceral,
but not subcutaneous adipose tissue. Deposition of excess
adipose tissue in the visceral cavity has been linked to
several obesity-associated diseases, including hypertension
and diabetes [18, 19]. Mechanisms for increased risk from
6 International Journal of Hypertension
visceral adipose accumulation are not clear, but may relate
to increased metabolic activity of visceral adipose tissue [20].
Region-specific effects of obesity to increase visceral, but not
subcutaneous ACE2 activity, are consistent with increased
metabolic activity and a more pronounced impact of visceral
adipose tissue on obesity-associated diabetes. However, since
increased ACE2 activity would predictably lower local levels
of AngII, these results suggest that activated ACE2 may serve
as a compensatory protective mechanism. Alternatively, since
F4/80 mRNA abundance was increased in visceral adipose
tissue from HF-fed mice, increased ACE2 activity in the SVF
may have resulted from increased macrophage infiltration
to visceral adipose tissue of HF-fed mice. This finding
is consistent with results from studies demonstrating that
obesity is associated with more pronounced infiltration of
macrophages in visceral compared to subcutaneous adipose
tissue [21]. Moreover, this conclusion is supported by data
demonstrating that ACE2 activity in more purified popu-
lations of macrophages, such as peritoneal macrophages or
the bone marrow, was not increased by HF feeding. Thus,
increased ACE2 activity in the stromal vascular fraction of
HF-fed mice most likely arose from increased macrophage
infiltration to adipose tissue.
Given findings of increased ACE2 activity in the SVF
from visceral adipose tissue of HF-fed mice, we quanti-
fied effects of ACE2 deficiency in infiltrating leukocytes
on adipose inflammation and glucose homeostasis using
bone marrow transplantation. Bone marrow transplantation
has been previously employed to define the source of
macrophages infiltrating into adipose tissue with obesity [5]
and by our laboratory to determine the role of leukocyte
components of the RAS on developing atherosclerotic lesions
[2, 14]. Our results do not support a role for leukocyte ACE2
in the development of obesity in HF-fed mice. In addition,
consistent with previous studies, [2] systemic concentrations
of cholesterol and/or fatty acids were not influenced by ACE2
deficiency in leukocytes. Moreover, deficiency of ACE2 in
bone-marrow-derived stem cells had no effect on systemic
concentrations of renin or AngII, similar to previous studies
examining effects of renin deficiency in bone-marrow-
derived cells on atherosclerosis in western diet-fed LDLR−/−
mice [22].
A novel finding in this study was that ACE2 defi-
ciency in bone-marrow-derived stem cells increased mRNA
abundance of a macrophage marker (F4/80) and TNF-
α in the SVF from visceral adipose tissue. As described
above, increased mRNA abundance of F4/80 in the SVF
from ACE2 chimeric mice supports increased infiltration
of macrophages into adipose tissue. Increased infiltration
of macrophages into adipose tissue was associated with
elevated expression of TNF-α, a marker of M1 polarized
macrophages. TNF-α has a well-defined role in the develop-
ment of insulin resistance in both mice and humans [23–
26]. Moreover, previous studies demonstrated that AngII
increases secretion of TNF-α from RAW 264.7 macrophages
[27] and that blockade of AT1 receptors in bone marrow
stromal cells decreased TNF-αmRNA abundance [28]. Thus,
it is conceivable that increased levels of AngII released from
macrophages of ACE2-deficient mice [2] contributed to
elevated mRNA abundance of TNF-α in the SVF. Alterna-
tively, increased TNF-αmRNA abundance may have resulted
from increasedmacrophage infiltration into adipose tissue of
ACE2 chimeric mice. This possibility is unlikely since other
markers of M1macrophage polarization, such as CCR2, were
not increased in the SVF from ACE2 chimeric mice.
It should be noted that effects of leukocyte ACE2 defi-
ciency to promote F4/80 mRNA abundance in SVF of high
fat-fed mice, while significant, were relatively modest (2-
fold increase in F4/80 mRNA abundance in ACE2-deficient
chimeras). Previous investigators have used bone marrow
transplantation with creation of chimeric mice to examine
effects of CCR2 deficiency in leukocytes on F4/80 expression
in adipose tissue of high-fat-fed mice. Leukocyte deficiency
of CCR2, the major receptor for the chemokine MCP-1,
resulted in a 50% reduction in F4/80 expression in adipose
tissue [29]. Thus, the magnitude of the effect of ACE2
deficiency to promote F4/80 mRNA abundance is consistent
with other leukocyte chimeric manipulations.
To our knowledge, this is the first report that deficiency
of leukocyte ACE2 can modulate the development of glucose
intolerance in obese mice. Moreover, the magnitude of effect
of ACE2 deficiency in bone-marrow-derived cells to promote
glucose intolerance in HF mice was most likely under-
estimated in the present study due to the pronounced glucose
intolerance present in irradiated 4 month HF-fed mice.
Indeed, impaired glucose tolerance in chimeric mice lacking
ACE2 in leukocytes was supported by increased blood
concentrations of glycosylated hemoglobin, a more stable
blood predictor of type 2 diabetes [30]. Since plasma insulin
concentrations in the present study were not influenced by
leukocyte ACE2 deficiency, then these results suggest that
the degree of glucose intolerance in chimeric ACE2-deficient
mice was not sufficient to further augment hyperinsulinemia
in chronic 4 month HF-fed mice. Indeed, plasma insulin
concentrations in the present study (>8 ng/mL) in 4 month
HF-fed mice were greater than those observed in 2 month
HF-fed mice (2 months, 5 ng/mL [31]). Importantly, glucose
intolerance was slightly augmented in chimeric mice lacking
ACE2 in leukocytes even though these mice exhibited a
similar level of obesity compared to wild type controls. In
comparison to other studies examining leukocyte deficiency
of proteins known to regulate glucose homeostasis, previous
studies demonstrated that deficiency of IL-10 [32], leptin
[33], toll 4 receptors [34], or PAI-1 [35] had no effect on glu-
cose tolerance in HF-fed mice. Thus, given negative results
from leukocyte deficiency of these well-known regulators
of glucose homeostasis, it is interesting that deficiency of
ACE2 in leukocytes modestly impaired glucose homeostasis
in obese mice.
A limitation of this study is that the relative role of
AngII versus Ang-(1–7) in the effects of bone marrow
ACE2 deficiency on adipose tissue inflammation and glucose
homeostasis was not defined. Previous studies demonstrated
that mas receptor deficiency in FVB/N mice resulted in
marked changes in lipid profiles and glucose homeosta-
sis [36]. In addition, chronic infusion of Ang-(1–7) to
fructose-fed rats reduced fasting insulin levels and enhanced
insulin signaling pathways (IRS-1/PI3K/Akt) in liver, skeletal
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muscle, and adipose tissue [37]. An elegant study by Santos
et al. utilized a transgenic Sprague-Dawley rat to overexpress
Ang-(1–7) systemically and found that plasma triglyceride
and cholesterol levels were decreased and whole body insulin
sensitivity was enhanced [38]. This group also noted that
Ang-(1–7) significantly increased adiponectin levels in rat
adipocytes [38]. These results suggest that reductions in
Ang-(1–7) may have contributed to the observed effects of
leukocyte ACE2 deficiency. Alternatively, since AngII, but not
Ang-(1–7), increased adhesion of monocytes to endothelial
cells, [2] then AngII may have mediated effects of chimeric
ACE2 deficiency. Further studies are needed to clarify the role
of the AngII/Ang-(1–7) balance in effects of ACE2 deficiency
on adipose inflammation and glucose homeostasis in obese
mice.
5. Conclusions
In conclusion, deficiency of ACE2 in leukocytes modestly
promoted inflammation in the stromal vascular fraction
from visceral adipose tissue and augmented glucose intoler-
ance inmice with diet-induced obesity. Future studies should
address the role of ACE2 in inflammation of human adipose
tissue and type 2 diabetes.
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